A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service

Proportion of patients in clinical remission,Number and proportion achieving specific criteria for clinical remission,Number and proportion of super-responders,Number and proportion of responders,Number and proportion of non-responders

Asthma is a common lung condition that causes occasional breathing difficulties and affects
 around 5.4 million people in the UK of all ages. Common symptoms can include wheezing when
 breathing, breathlessness, a tight chest and coughing. However, these symptoms can get worse
 and lead to an asthma attack which can be fatal.
 
 There is currently no cure for asthma but there are treatments that can help keep the
 symptoms under control. The main types of treatment include reliever inhalers used when
 needed quickly to reverse asthma symptoms for a short time, and preventer inhalers that are
 used everyday to prevent symptoms for starting. Unfortunately, not all patients are able to
 control their asthma on these treatments alone. Biologic treatments, also known as monoclonal
 antibodies, have been introduced to treat certain types of severe asthma over recent years.
 These specialist treatments use antibodies produced from cells in a laboratory to help reduce
 inflammation and might offer the possibility of higher levels of disease control including
 the reduction or absence of symptoms and normal lung function. This higher level of disease
 control is called remission.
 
 This study aims to understand whether or not remission is possible in patients with severe
 asthmas treated with biologics in the NHS. This study will take place a 4 specialist asthma
 centres in the UK and seeks to include retrospective data from approximately 450 adult
 patients that were treated with biologics as part of routine care between 01 October 2021 and
 30 September 2022. Data will be collected directly from medical records and entered into the
 study database in a pseudonymised format by members of the direct care team ready for
 analysis.